Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Invesco Water Resources ETF (PHO)

Invesco Water Resources ETF (PHO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Xylem Inc_ logo seen displayed on a smartphone_By Rafael Henrique
Xylem Stock: Analyst Estimates & Ratings Barchart - Tue Aug 18, 4:56AM CDT

Xylem has underperformed the broader market, while analysts remain moderately optimistic about its future prospects.

$SPX : 7,674.37 (+0.43%)
PHO : 72.19 (+0.75%)
XYL : 113.42 (-0.02%)
Pentair Canada facility building in Cambridge, By JHVEPhoto
Do Wall Street Analysts Like Pentair Stock? Barchart - Mon Aug 17, 5:38AM CDT

Pentair has significantly underperformed the market, but analysts remain moderately optimistic, supported by consistent earnings beats and potential price-target upside.

PNR : 64.40 (+0.97%)
$SPX : 7,674.37 (+0.43%)
PHO : 72.19 (+0.75%)
Photocure Welcomes FDA Proposal to Initiate the Reclassification of Blue Light Cystoscopy Systems from Class III to Class II PR Newswire - Fri Aug 14, 11:18AM CDT

OSLO, Norway , Aug. 14, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announced that the U.S. Food and Drug Administration (FDA) has published a  proposed...

PHO : 72.19 (+0.75%)
Cost neutrality of BLC versus WLC in a real-world setting demonstrated by new OPTUM study in the U.S. PR Newswire - Tue Aug 11, 1:52AM CDT

OSLO, Norway , August 11, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO) , the Bladder Cancer Company, announces the publication of the 'Healthcare Resource Utilization and Costs Associated...

PHO : 72.19 (+0.75%)
Photocure ASA: Results for the second quarter of 2026 PR Newswire - Wed Jul 29, 1:25AM CDT

OSLO, Norway , July 29, 2026 /PRNewswire/ --  Photocure ASA (OSE: PHO) today reported Hexvix ® /Cysview ® revenues of NOK 140.0 million in the second quarter...

PHO : 72.19 (+0.75%)
MarketBeat.com
These 3 Water ETFs Could be Quiet Winners From Infrastructure Spending MarketBeat - Tue Jul 14, 9:45AM CDT

As data centers strain water systems, FIW, PHO, and CGW offer investors ETF-based access to water utilities, infrastructure, and equipment firms, each with distinct fees and concentration.

CGW : 65.10 (+0.37%)
FIW : 111.14 (+0.62%)
PHO : 72.19 (+0.75%)
IDXX : 556.93 (+2.03%)
ECL : 281.63 (+0.05%)
Photocure and Artera to partner on digital pathology AI test evaluation for Bladder Cancer PR Newswire - Mon Jun 8, 12:29PM CDT

OSLO, Norway , June 8, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO) , the Bladder Cancer Company, and Artera, a leading precision medicine company, announce launch of a joint research initiative....

PHO : 72.19 (+0.75%)
Photocure ASA to Acquire Vesica Health Inc., Strengthening Leadership in Bladder Cancer Diagnostics PR Newswire - Thu Jun 4, 10:46AM CDT

OSLO, Norway , June 4, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO) , a leader in bladder cancer diagnostics, today announced the signing and successful completion of its acquisition of Vesica...

PHO : 72.19 (+0.75%)
AUA 2026: new studies demonstrated Blue Light Cystoscopy benefits in high-risk NMIBC management and cost comparison study PR Newswire - Mon May 18, 10:36AM CDT

OSLO, Norway , May 18, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the presentation of two Photocure-supported abstracts at the American Urological Association...

PHO : 72.19 (+0.75%)
Photocure ASA: Results for the first quarter of 2026 PR Newswire - Thu May 7, 1:13AM CDT

OSLO, Norway , May 7, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix ® /Cysview ® revenues of NOK 139.0 million in the first quarter of 2026 (Q1 2025: NOK...

PHO : 72.19 (+0.75%)

Barchart Exclusives

As Cerebras Launches a New, Record-Setting AI Accelerator, Here’s How You Should Play CBRS Stock Barchart - 1 hour ago
Cerebras’ new CS-4 AI accelerator could strengthen its position, but with CBRS shares remaining highly volatile, is this the right entry point? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.